Syngene International recently faced a significant downturn in its stock performance, with shares plummeting 13.22% to an intra-day low of ₹650.05 on the National Stock Exchange. This decline comes in the wake of the company’s latest financial results, which revealed an 8.11% drop in standalone net profit for the first quarter of FY25, falling to ₹174.40 crore from ₹189.80 crore in the same quarter of the previous fiscal year.

Earnings and Revenue Insights

In terms of earnings per share (EPS), Syngene International reported a decrease to ₹4.34 for the quarter ending March 31, 2025, down from ₹4.73 in the corresponding period last year. Despite these challenges, the company’s revenue showed positive growth, reaching ₹948.40 crore in March 2025, which reflects a 9.68% increase compared to ₹864.70 crore in Q4 FY24.

• Operating Profit (EBITDA): The EBITDA also saw an uptick, amounting to ₹328.40 crore in the last quarter of FY25, marking a 4.39% year-on-year increase from ₹314.60 crore in Q4 FY24.

Dividend Announcement

In addition to the financial results, Syngene’s board has declared a final dividend of ₹1.25 per equity share, based on a face value of ₹10. The record date for this dividend is set for June 27, 2025, and shareholders can expect payment within 30 days following approval.

Strategic Developments

Peter Bains, the Managing Director and CEO of Syngene International, emphasized a significant milestone for the company—acquiring a state-of-the-art biologics manufacturing facility in the United States. This acquisition enhances Syngene’s standing in the rapidly growing biologics CDMO sector and provides a strategic advantage in the U.S. market. Bains expressed optimism about the future, stating, “We anticipate ongoing business momentum, driven by both small and large molecule projects, alongside new pilot programs and the evolution of existing pilot projects in discovery services.”

Stock Performance Overview

Syngene International’s stock has experienced a turbulent period, with a 10% decline in the last five trading days alone. Over the past month, the share price has decreased by 9%, and investors have seen more than 25% of their wealth evaporate over the last six months. In the past year, the stock has corrected by 5.6%.

This recent performance underscores the volatility in the market and highlights the need for potential investors to consider both the challenges and opportunities that lie ahead for Syngene International.